Background and Clinical Evidence

Cynacalet is a parathyroid hormone (PTH) inhibitor and has demonstrated efficacy in lowering serum calcium in patients with chronic kidney disease. In Phase 3 clinical trials, reductions in serum calcium and PTH were statistically significant, but long‑term safety data raised concerns about cardiovascular event risk. Because of these risks, the EMA granted initial approval, but decided to withdraw it after reviewing additional data.

Positioning Relative to Competing Drugs

Cynacalet’s advantage over existing vitamin D therapies was its rapid calcium control. However, next‑generation agents such as the newer calcimimetic Evolisite are regarded as safer and more efficacious. The emergence of these competitors has made market differentiation increasingly difficult.

Reimbursement and Market Entry Constraints

Reimbursement in major European countries was implemented rapidly after approval, but the withdrawal is expected to prolong the re‑evaluation process. Patients and clinicians will need to switch to alternative therapies, and recovering reimbursement for existing prescriptions may be challenging. This will impact hospital budgets and patient cost burdens.

Market Size and Impact

When Cynacalet was first approved, the European market size was estimated at roughly €200 million. The withdrawal will cause a sharp decline in that revenue, with market share likely to be redistributed to competing products. In the long term, drug development is expected to place greater emphasis on safety.